Elevance Health 3Q 2024 Earnings Presentation October 17, 2024 -- 1 of 13 -- 2 Key Highlights • Elevance Health third quarter results were below expectations primarily due to the unprecedented mix shift in Medicaid membership related to eligibility redeterminations • 3Q 2024 operating revenue of $44.7B grew 5.3% year-over-year • 3Q 2024 adjusted diluted EPS of $8.37 • 3Q 2024 adjusted operating gain of $2.4B 3Q 2024 Results 1 • 2024 adjusted diluted EPS guidance of approximately $33 accounts for the timing mismatch between Medicaid rates and the higher acuity of our members, partially offset by targeted medical management and proactive actions to enhance operating efficiencies • We now expect the 2024 benefit expense ratio to be approximately 88.5% and operating cash flow to be approximately $4.5 billion, principally due to headwinds in the Medicaid business • We expect strong acceleration in revenue growth in 2025, in line with our long-term growth algorithm, in the high single-digit percentage range and, at this point in time, growth in 2025 adjusted diluted EPS in at least the mid single-digit percentage range • Commercial businesses performing well and on track to achieve financial objectives; individual exchange business delivering particularly strong growth, as we prepare to expand our footprint in 2025 • Scaling our enterprise flywheel for growth as we accelerate capabilities and services in Carelon through an expanding customer base and the buildout of a home-based care management business 2024 & 2025 Outlook 2 • Earnings power of our diverse and complementary businesses remains strong, and we are making the right investments to position Elevance Health for long-term, sustainable growth • Issues impacting the Medicaid managed care industry are timebound, and we are partnering with states to ensure rising acuity is reflected in rates • Pleased with positioning for 2025 Medicare Advantage bids, which promote access to high-quality, comprehensive care for our members; we expect to grow in line or slightly better than the market • Expanding Carelon capabilities in support of long-term growth and value creation Strategic Focus Areas 3 -- 2 of 13 -- 33 Key Highlights • Elevance Health third quarter results reflect a challenging and dynamic operating environment primarily due to the timing mismatch between Medicaid rates and acuity • Operating revenue of $44.7B on improved premium yields in Health Benefits, partially offset by the impact of membership attrition in Medicaid • Benefit expense ratio of 89.5% increased 270 basis points driven primarily by pressure in Medicaid • Adjusted operating expense ratio of 9.6% highlights disciplined and proactive expense management 3Q 2024 Results Change 3Q 2023 3Q 2024 Elevance Health 5.3% $42.5B $44.7B Operating Revenue 1 270 bps 86.8% 89.5% Medical Loss Ratio (150) bps 11.1% 9.6% Adjusted Operating Expense Ratio1,2 (5.6%) $2.5B $2.4B Adjusted Operating Gain1,2 (70) bps 6.0% 5.3% Adjusted Operating Margin 1,2 11.8% $493M $551M Net Investment Income (6.9%) $8.99 $8.37 Adjusted diluted EPS2 $0.1B $2.6B $2.7B Operating Cash Flow 1. See “Basis of Presentation” on slide 10 herein. 2. See “GAAP Reconciliation” on slides 11 and 12 herein. Enterprise Results -- 3 of 13 -- 44 Key Highlights • Health Benefits revenue growth re- accelerating • Operating revenue grew 4.2% driven primarily by higher premium yields, partially offset by declines in Medicaid membership • Operating gain was impacted by unfavorable mix shift in Medicaid membership related to eligibility redeterminations • Membership of 45.8M reflects attrition in Medicaid, partially offset by strong growth in Employer Group fee-based and ACA health plan membership Change 3Q 2023 3Q 2024 Health Benefits 4.2% $36.7B $38.3B Operating Revenue 1 (12.5%) $1.8B $1.6B Operating Gain1 (80) bps 5.0% 4.2% Operating Margin 1 (3.3%) 47.3M 45.8M Membership 2 1. See “Basis of Presentation” on slide 10 herein. 2. Health Benefits Membership for the three months ended September 30, 2023, is restated to reflect a change in BlueCard® membership to align to the Blue Cross Blue Shield Association reporting methodology. For the three months ended September 30, 2023, BlueCard® membership has been restated lower by 19K. Health Benefits 3Q 2024 Results -- 4 of 13 -- 55 Key Highlights • Carelon is delivering innovative solutions aligned with our strategy of controlling the levers than matter • Serves as the enterprise flywheel for growth, integrating physical, behavioral, social and pharmacy services to deliver whole health, affordably • CarelonRx operating revenue of $9.1 billion includes the acquisition of Paragon Healthcare and strong external member growth; operating gain of $619 million reflects growth in product revenue • Carelon Services operating revenue of $4.6 billion grew 32% driven by the launch and growth of risk-based products and is on track to exceed the upper end of our initial outlook of low twenties percentage revenue growth; operating gain of $184 million 3Q 2024 Results Change 3Q 2023 3Q 2024 Carelon 14.6% $12.0B $13.8B Operating Revenue 1 20.0% $669M $803M Operating Gain1 20 bps 5.6% 5.8% Operating Margin 1 3.8% 77.3M 80.2M Adjusted Scripts (3.3%) 104.8M 101.3M Consumers Served 1. See “Basis of Presentation” on slide 10 herein. Health Services -- 5 of 13 -- 66 Flywheel Supports Our Long-Term Growth Algorithm Health Benefits Optimize the Core Invest in Growth Accelerate Targeting at least 12% average annual growth in Adjusted Diluted Earnings Per Share Approximately 46M medical members balanced across commercial, Medicaid and Medicare, leveraging the assets and capabilities of Carelon to accelerate growth Integrated portfolio of whole health solutions connecting care across physical, behavioral, social, and pharmacy needs to bend the cost curve, enhance consumer experiences, and deliver whole health, affordably Health Services -- 6 of 13 -- 77 Adjusted Operating Gain – Upper Single Digit to Low Double Digit CAGR 1 Long-Term Growth Algorithm Revenue Growth Upper Single Digit CAGR 1 Adjusted Operating Margin Expanding to 6.5% - 7.0% by 2027 Capital Deployment Approximately 4% Contribution to Adjusted Diluted EPS CAGR 1 Health Benefits Mid to Upper Single Digit CAGR Driven by membership growth, cost trend, geographic expansion, and growth in specialized populations Carelon Services Upper Teens to Low Twenties CAGR Driven by risk-based revenue growth including M&A CarelonRx Low-Double Digit CAGR Driven by script volumes and drug mix Transforming our business processes by leveraging new technologies across operations Commitment to operating efficiency and optimizing core businesses Effective medical management Underwriting discipline Share Repurchases Organic Reinvestment Programmatic M&A targeting integrated solutions that strengthen health plan competitiveness + + Targeting at least 12% average annual growth in Adjusted Diluted EPS 1. CAGR = Compound Annual Growth Rate Target. -- 7 of 13 -- 88 Committed to Strong Growth Over the Long-Term M&A/ Organic Reinvestment 50% Share Repurchase 30% Dividends 20% 5.3% 6.5% – 7.0% 2022 2027 Target $156B Upper Single Digit CAGR2,3 2022 2027 Target Elevance Health 5.8% Mid to Upper Single Digit 2022 2027 Target $41B Mid Teens CAGR2,3 2022 2027 Target Carelon 4 4.3% 5.5% – 6.5% 2022 2027 Target $138B Mid to Upper Single Digit CAGR2,3 2022 2027 Target Health Benefits Capital Allocation Targeting at least 12% average annual growth in Adjusted Diluted EPS Operating Margin 1 Revenue1 (in Billions) 1. 2022 Operating Revenue and Operating Margin for Health Benefits, Carelon, and Elevance Health have been updated to reflect restated financials. 2. CAGR = Compound Annual Growth Rate Target. 3. Five-Year CAGR target for 2022 – 2027. 4. The CAGR target for revenue from 2022 – 2027 and the operating margin target in 2027 for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx, and (ii) an upper teens to low twenties revenue CAGR and mid to upper single-digit operating margin for Carelon Services. -- 8 of 13 -- 9 Forward-Looking Statements This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations. -- 9 of 13 -- 10 Non-GAAP Measures and Basis of Presentation This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available on the last slide of this document. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. -- 10 of 13 -- 11 11 Elevance Health GAAP Reconciliation — Shareholders’ Net Income and Shareholders’ Earnings Per Diluted Share Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2023 2024 Change 2023 2024 (In millions, except per share data) 8.4% $5,131 $5,562 (21.2%) $1,289 $1,016 Shareholders' net income Add / (Subtract): 5 680 2 669 Litigation and settlement expenses1 697 268 697 268 Business optimization charges 1 358 371 124 125 Net losses on financial instruments 668 400 212 122 Amortization of other intangible assets 154 158 73 42 Transaction and integration related costs1 — (201) — 39 Loss (gain) on sale of business (470) (432) (270) (329) Tax impact of non-GAAP adjustments 1,412 1,244 838 936 Net adjustment items 4.0% $6,543 $6,806 (8.2%) $2,127 $1,952 Adjusted shareholders' net income 10.4% $21.56 $23.81 (20.0%) $5.45 $4.36 Shareholders’ earnings per diluted share Add / (Subtract): 0.02 2.91 0.01 2.87 Litigation and settlement expenses1 2.93 1.15 2.95 1.15 Business optimization charges 1 1.50 1.59 0.52 0.54 Net losses on financial instruments 2.81 1.71 0.90 0.52 Amortization of other intangible assets 0.65 0.68 0.31 0.18 Transaction and integration related costs1 — (0.86) — 0.17 Loss (gain) on sale of business (1.97) (1.85) (1.14) (1.41) Tax impact of non-GAAP adjustments 5.93 5.33 3.54 4.01 Net adjustment items 6.0% $27.49 $29.14 (6.9%) $8.99 $8.37 Adjusted shareholders’ earnings per diluted share Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2023 2024 Change 2023 2024 (In millions) 8.7% $6,714 $7,298 (17.0%) $1,654 $1,373 Income before income tax expense (1,296) (1,524) (493) (551) Net investment income — (201) — 39 Loss (gain) on sale of business 358 371 124 125 Net losses on financial instruments 771 845 259 300 Interest expense 668 400 212 122 Amortization of other intangible assets (0.4%) $7,215 $7,189 (19.8%) $1,756 $1,408 Reportable segments operating gain 1. Adjustment item resides in the Corporate & Other reportable segment. -- 11 of 13 -- 12 12 Elevance Health GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and 2024 Outlook Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2023 2024 Change 2023 2024 (In millions) 0.9% $15,088 $15,221 (3.7%) $5,470 $5,269 Operating expense Add / (Subtract): (5) (680) (2) (669) Litigation and settlement expenses1 (697) (268) (697) (268) Business optimization charges 1 (154) (158) (73) (42) Transaction and integration related costs1 (856) (1,106) (772) (979) Net adjustment items (0.8%) $14,232 $14,115 (8.7%) $4,698 $4,290 Adjusted operating expense 1.9% $127,755 $130,215 5.3% $42,480 $44,719 Operating revenue (10) bp 11.8% 11.7% (110) bp 12.9% 11.8% Operating expense ratio (30) bp 11.1% 10.8% (150) bp 11.1% 9.6% Adjusted operating expense ratio Nine Months Ended Sep 30 Three Months Ended Sep 30 Change 2023 2024 Change 2023 2024 (In millions) (0.4%) $7,215 $7,189 (19.8%) $1,756 $1,408 Reportable segments operating gain Add / (Subtract): 5 680 2 669 Litigation and settlement expenses1 697 268 697 268 Business optimization charges 1 154 158 73 42 Transaction and integration related costs1 856 1,106 772 979 Net adjustment Items 2.8% $8,071 $8,295 (5.6%) $2,528 $2,387 Reportable segments adjusted operating gain Full Year 2024 Outlook Approximately $26.50 Shareholders’ earnings per diluted share Add / (Subtract): $2.93 Litigation and settlement expenses1 $2.21 Amortization of other intangibles $1.93 Net losses on financial instruments $1.15 Business optimization charges 1 $1.03 Transaction and integration related costs1 ($0.86) Gain on sale of business Approximately ($1.89) Tax impact of non-GAAP adjustments $6.50 Net adjustment items Approximately $33.00 Adjusted shareholders’ earnings per diluted share 1. Adjustment item resides in the Corporate & Other reportable segment. -- 12 of 13 -- -- 13 of 13 --